Abstract:Background Glioblastoma is an aggressive primary brain malignancy that is characterized by a highly suppressive tumor microenvironment, including myeloid-derived suppressor cells, tumor-associated macrophages, and brain-resident microglia, but lacking significant T cell infiltration. 1 2 This phenotype is reflected in the recently developed QKi -/- Pten -/- P53 -/- (QPP) tumor model, 3 which we show is resistant to PD1 or CTLA-4 blockade, but sensitive to agonists of the innate immune sensor Stimulator of Interferon Genes (STING). We have previously shown that agonists of the innate dsDNA-sensing cGAS-STING pathway are capable of proinflammatory repolarization in in vitro models of suppressive myeloid cells, although their function in the context of the Glioblastoma myeloid compartment in vivo remains poorly understood. 4 Methods We utilized the synthetic cyclic di-nucleotide STING agonists IACS-8803 (8803) and ML-RR-S2-CDA (MLRR) to assess survival and tumor immune infiltrate functional reprogramming in two orthotopic transplantable human and murine Glioblastoma tumor models, U87 and the recently developed QPP8 (Qki -/- Pten -/- P53 -/- ). Using in vitro models of M2-polarized microglia, we investigated the ability of natural (2'3'-cGAMP) and synthetic (MLRR and 8803) STING agonists to reverse immunosuppressive microglial polarization. Results We found that intratumoral delivery of STING agonists significantly prolonged survival in the murine QPP8 orthotopic Glioblastoma tumor model, in contrast to checkpoint blockade which had no benefit on survival. In huNOG-EXL mice engrafted with human hematopoietic stem cells implanted with orthotopic U87 Glioblastoma, intratumoral delivery of STING agonists significantly prolonged survival and reduced expression of CD163 and CD206 on human tumor-infiltrating myeloid populations. Preliminary data suggests that in vitro suppressively-polarized microglia reduce expression of M2 functional markers, and increase expression of iNOS, PD-L1, CD80, and CD86 in a STING agonist potency-dependent manner. Conclusions We found that STING agonists can induce curative responses in checkpoint-refractory murine Glioblastoma models and mediate significant extension of survival in a humanized mouse U87 xenograft setting. This prolonged survival is associated with a decrease in immunosuppressive M2 functional markers in human tumor infiltrating myeloid populations. Additionally, M2-polarized microglia demonstrated a reduction in M2 functional markers and upregulation of proinflammatory M1 markers following treatment with STING agonists. Together these results indicate that delivery of STING agonists can induce proinflammatory repolarization of the Glioblastoma myeloid stroma, including both infiltrating myeloid populations and brain-resident microglia, to drive prolonged survival in refractory models of Glioblastoma. References Gabrusiewicz K, Rodriguez B, Wei J, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight 2016; 1 (2). Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017; 31 (3):326–41. Shingu T, Ho AL, Yuan L, et al. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet 2017; 49 (1):75–86. Ager C, Boda A, Rajapakshe K, et al. (2021) “High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. JITC (in press) Ethics Approval All experiments were conducted according to protocols approved by the University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee.

Immu-19. Preclinical Therapeutic Activity And Pet Imaging Of Sting Agonist 8803 In Glioblastoma

STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

763 Intratumoral delivery of high potency STING agonists modulates the immunosuppressive myeloid compartment and induces curative responses in checkpoint-refractory glioblastoma models

Abstract LB335: Establishment of the effective dose of the STAT3 inhibitor WP1066 used in combination with STING activation for reprograming the preclinical glioma microenvironment

STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models

Development of STING probes and visualization of STING in multiple tumor types

[ 89 Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models

ImmunoPET imaging of TIGIT in the glioma microenvironment

Sequential Release HydroLipo System for STING Gene Epigenetic Reprogramming and Immune Activation in Glioblastoma

Preclinical Evaluation of 131I/18F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging

Engineered PLGA Microparticles for Long-Term, Pulsatile Release of STING Agonist for Cancer Immunotherapy

Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.

STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.

DDEL-08. NOVEL COMBINATION THERAPY USING PI3KINASE INHIBITION AND IMMUNE BASED THERAPY FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME

NIMG-48. TLR7/8-AGONIST-LOADED NANOPARTICLES REPROGRAM TUMOR-ASSOCIATED MYELOID CELLS FOR EFFECTIVE IMMUNOTHERAPY OF EXPERIMENTAL GLIOMA AND MRI-BASED TREATMENT MONITORING

Abstract 2457: Brain derived endothelial cells as a mediator of cGAS-STING driven anti-tumor efficacy in glioblastoma

IMMU-42. DUAL ACTIVATION OF THE cGAS-STING PATHWAY AND AIM2-INDUCED PYROPTOSIS BY TUMOR-TREATING FIELDS PRODUCES ANTI-TUMOR IMMUNITY IN GLIOBLASTOMA

Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration

Abstract 6644: A Comprehensive in Vitro and in Vivo System to Evaluate STING Agonist Efficacy in Cancer Therapeutics

In situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response

Abstract 5235: Combination STING agonist and NK cellular therapy in patient derived organotypic tumor spheroids